Search Results - "Yi, Jingyan"

  • Showing 1 - 17 results of 17
Refine Results
  1. 1

    Hormonal influence: unraveling the impact of sex hormones on vascular smooth muscle cells by Jia, Keran, Luo, Xin, Yi, Jingyan, Zhang, Chunxiang

    Published in Biological research (04-09-2024)
    “…Sex hormones play a pivotal role as endocrine hormones that exert profound effects on the biological characteristics and vascular function of vascular smooth…”
    Get full text
    Journal Article
  2. 2

    Integrated bioinformatics analysis and screening of hub genes in polycystic ovary syndrome by Qiao, Gan, Xing, Jinshan, Luo, Xin, Zhang, Chunxiang, Yi, Jingyan

    Published in Endocrine (01-12-2022)
    “…Purpose Polycystic ovary syndrome (PCOS) is one of the most common endocrine and metabolic disorders, posing a serious threat to the health of women. Herein,…”
    Get full text
    Journal Article
  3. 3

    Comprehensive analysis of LASS6 expression and prognostic value in ovarian cancer by Xing, Jinshan, Yi, Jingyan

    Published in Journal of ovarian research (07-09-2021)
    “…Ceramide plays an important role in the occurrence and development of tumor. The synthesis of ceramide needs the participation of LASS. Current studies have…”
    Get full text
    Journal Article
  4. 4

    The utilization of nanotechnology in the female reproductive system and related disorders by Luo, Xin, Jia, Keran, Xing, Jinshan, Yi, Jingyan

    Published in Heliyon (15-02-2024)
    “…The health of the reproductive system is intricately linked to female fertility and quality of life. There has been a growing prevalence of reproductive system…”
    Get full text
    Journal Article
  5. 5

    BTF3 confers oncogenic activity in prostate cancer through transcriptional upregulation of Replication Factor C by Zhang, Yuan, Gao, Xiang, Yi, Jingyan, Sang, Xiaolin, Dai, Zhihong, Tao, Zhiwei, Wang, Min, Shen, Lanlin, Jia, Yaxun, Xie, Daqing, Cheng, Hailing, Liu, Zhiyu, Liu, Pixu

    Published in Cell death & disease (05-01-2021)
    “…High levels of Basic Transcription Factor 3 (BTF3) have been associated with prostate cancer. However, the mechanisms underlying the role of BTF3 as an…”
    Get full text
    Journal Article
  6. 6

    Micelle encapsulation zinc‐doped copper oxide nanocomposites reverse Olaparib resistance in ovarian cancer by disrupting homologous recombination repair by Yi, Jingyan, Luo, Xin, Xing, Jinshan, Gedanken, Aharon, Lin, Xiukun, Zhang, Chunxiang, Qiao, Gan

    Published in Bioengineering & translational medicine (01-05-2023)
    “…Micelle Encapsulation Zinc‐doped copper oxide nanocomposites (MEnZn‐CuO NPs) is a novel doped metal nanomaterial prepared by our group based on Zinc doped…”
    Get full text
    Journal Article
  7. 7

    Integrating network pharmacology and experimental verification to explore the pharmacological mechanisms of asparagus against polycystic ovary syndrome by Xing, Jinshan, Luo, Xin, Jia, Keran, Liu, Shuang, Chen, Shaokun, Qiao, Gan, Zhang, Chunxiang, Yi, Jingyan

    Published in Journal of ovarian research (01-07-2023)
    “…Polycystic ovary syndrome (PCOS) is a common reproductive endocrine disorder in women of reproductive age that still lacks effective treatment. Inflammation is…”
    Get full text
    Journal Article
  8. 8

    Inhibition of SGK1 confers vulnerability to redox dysregulation in cervical cancer by Wang, Min, Xue, Yijue, Shen, Lanlin, Qin, Pan, Sang, Xiaolin, Tao, Zhiwei, Yi, Jingyan, Wang, Jia, Liu, Pixu, Cheng, Hailing

    Published in Redox biology (01-06-2019)
    “…Cervical cancer has poor prognosis and patients are often diagnosed at advanced stages of the disease with limited treatment options. There is thus an urgent…”
    Get full text
    Journal Article
  9. 9

    The c.323 G>C mutation in LORICRIN causes new-found late-onset autosomal dominant loricrin keratoderma in a Chinese Han Pedigree by Gao, Xiaojie, Li, Hua, Zhao, Songhua, Li, Xiabin, Zhao, Jiao, Long, Yang, Zhang, Jun, Liao, Yongmei, Li, Shengbiao, Guo, Kai, Yi, Jingyan, Chen, Shaokun, Ma, Mingyi

    Published in Journal of dermatological science (01-04-2022)
    “…Loricrin keratoderma is a rare early-onset autosomal dominant skin disorder. At present, no clinical reports have been published on characteristics of…”
    Get full text
    Journal Article
  10. 10

    Ferredoxin 1 regulates granulosa cell apoptosis and autophagy in polycystic ovary syndrome by Xing, Jinshan, Qiao, Gan, Luo, Xin, Liu, Shuang, Chen, Shaokun, Ye, Geng, Zhang, Chunxiang, Yi, Jingyan

    Published in Clinical science (1979) (31-03-2023)
    “…Polycystic ovary syndrome (PCOS), a common reproductive endocrine disorder in women of reproductive age, causes anovulatory infertility. Increased apoptosis of…”
    Get more information
    Journal Article
  11. 11

    Research update on the anticancer effects of buparlisib by Xing, Jinshan, Yang, Jun, Gu, Yingjiang, Yi, Jingyan

    Published in Oncology letters (01-04-2021)
    “…Buparlisib is a highly efficient and selective PI3K inhibitor and a member of the 2,6-dimorpholinopyrimidine-derived family of compounds. It selectively…”
    Get full text
    Journal Article
  12. 12

    Targeting the EphB4 receptor tyrosine kinase sensitizes HER2-positive breast cancer cells to Lapatinib by Ding, Jinlei, Yao, Yating, Huang, Gena, Wang, Xiaonan, Yi, Jingyan, Zhang, Nan, Liu, Chongya, Wang, Kainan, Zhang, Yuan, Wang, Min, Liu, Pixu, Ye, Mingliang, Li, Man, Cheng, Hailing

    Published in Cancer letters (10-04-2020)
    “…Clinical data analysis reveals that the expression of the EphB4 receptor tyrosine kinase is significantly elevated in HER2-positive breast cancer and high…”
    Get full text
    Journal Article
  13. 13

    Network Pharmacology Analysis and Experimental Pharmacology Study Explore the Mechanism of Asparagus against Glioblastoma by Luo, Xin, Xing, Jinshan, Gu, Yingjiang, Qiao, Gan, Liu, Minghua, Yi, Jingyan

    Published in Journal of food biochemistry (08-02-2023)
    “…Glioblastoma (GBM) is the most malignant primary brain tumor, and there is an urgent need to explore effective therapeutic strategies to improve the prognosis…”
    Get full text
    Journal Article
  14. 14

    Inhibition of BTF3 sensitizes luminal breast cancer cells to PI3Kα inhibition through the transcriptional regulation of ERα by Ding, Jinlei, Wang, Xiaonan, Zhang, Yuan, Sang, Xiaolin, Yi, Jingyan, Liu, Chongya, Liu, Zundong, Wang, Min, Zhang, Nan, Xue, Yijue, Shen, Lanlin, Zhao, Wenzhi, Luo, Fuwen, Liu, Pixu, Cheng, Hailing

    Published in Cancer letters (01-01-2019)
    “…Selective phosphatidylinositol 3 kinase (PI3K) inhibitors are being actively tested in clinical trials for ERα-positive (ER+) breast cancer due to the presence…”
    Get full text
    Journal Article
  15. 15

    MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer by Yi, Jingyan, Liu, Chongya, Tao, Zhiwei, Wang, Min, Jia, Yaxun, Sang, Xiaolin, Shen, Lanlin, Xue, Yijue, Jiang, Kui, Luo, Fuwen, Liu, Pixu, Cheng, Hailing

    Published in EBioMedicine (01-05-2019)
    “…While PARP inhibitors and CDK4/6 inhibitors, the two classes of FDA-approved agents, have shown promising clinical benefits, there is an urgent need to develop…”
    Get full text
    Journal Article
  16. 16

    Targeting P16INK4A in uterine serous carcinoma through inhibition of histone demethylation by Xiao, Zhen, He, Yingying, Liu, Chongya, Xiang, Lin, Yi, Jingyan, Wang, Min, Shen, Tingting, Shen, Lanlin, Xue, Yijue, Shi, Hong, Liu, Pixu

    Published in Oncology reports (01-05-2019)
    “…Uterine serous carcinoma (USC) is a subtype of endometrial cancer. Compared with endometrial endometroid carcinoma, the majority of USC cases are more…”
    Get full text
    Journal Article
  17. 17

    MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancerResearch in context by Jingyan Yi, Chongya Liu, Zhiwei Tao, Min Wang, Yaxun Jia, Xiaolin Sang, Lanlin Shen, Yijue Xue, Kui Jiang, Fuwen Luo, Pixu Liu, Hailing Cheng

    Published in EBioMedicine (01-05-2019)
    “…Background: While PARP inhibitors and CDK4/6 inhibitors, the two classes of FDA-approved agents, have shown promising clinical benefits, there is an urgent…”
    Get full text
    Journal Article